Overview

Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Regeneron Pharmaceuticals
Sanofi